PE20051156A1 - Formulaciones de matriz orales que comprenden licarbazepina - Google Patents

Formulaciones de matriz orales que comprenden licarbazepina

Info

Publication number
PE20051156A1
PE20051156A1 PE2005000316A PE2005000316A PE20051156A1 PE 20051156 A1 PE20051156 A1 PE 20051156A1 PE 2005000316 A PE2005000316 A PE 2005000316A PE 2005000316 A PE2005000316 A PE 2005000316A PE 20051156 A1 PE20051156 A1 PE 20051156A1
Authority
PE
Peru
Prior art keywords
hydrophilic
licarbazepine
formulations including
hydrophyl
matrix formulations
Prior art date
Application number
PE2005000316A
Other languages
English (en)
Inventor
Oskar Kalb
Marie-Christine Wolf
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0406379A external-priority patent/GB0406379D0/en
Priority claimed from GB0406738A external-priority patent/GB0406738D0/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PE20051156A1 publication Critical patent/PE20051156A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/12—Antiepileptics; Anticonvulsants for grand-mal

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)

Abstract

REFERIDA A UNA COMPOSICION FARMACEUTICA ORAL DE LIBERACION CONTROLADA QUE COMPRENDE 10,11-DIHIDRO-10-HIDROXI-5H-DIBENZ[b,f]AZEPIN-5-CARBOXAMIDA (LIACARZEPINA) Y UNA SUSTANCIA HIDROFILICA O LIPOFILICA HINCHABLE TAL COMO HIDROXIPROPILMETILCELULOSA ADECUADA PARA ADMINISTRARSE CADA DIA. DICHA COMPOSICION ES UTIL PARA EL TRATAMIENTO DE PACIENTES CON DESORDENES AFECTIVOS
PE2005000316A 2004-03-22 2005-03-18 Formulaciones de matriz orales que comprenden licarbazepina PE20051156A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0406379A GB0406379D0 (en) 2004-03-22 2004-03-22 Organic compounds
GB0406738A GB0406738D0 (en) 2004-03-25 2004-03-25 Organic compounds

Publications (1)

Publication Number Publication Date
PE20051156A1 true PE20051156A1 (es) 2006-02-13

Family

ID=34961345

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2005000316A PE20051156A1 (es) 2004-03-22 2005-03-18 Formulaciones de matriz orales que comprenden licarbazepina

Country Status (16)

Country Link
US (1) US20070196488A1 (es)
EP (1) EP1732519A1 (es)
JP (1) JP2007529564A (es)
AR (1) AR048318A1 (es)
AU (1) AU2005226910B2 (es)
BR (1) BRPI0509067A (es)
CA (1) CA2558787A1 (es)
EC (1) ECSP066860A (es)
IL (1) IL177826A0 (es)
MA (1) MA28527B1 (es)
MX (1) MXPA06010810A (es)
NO (1) NO20064808L (es)
PE (1) PE20051156A1 (es)
RU (1) RU2006137330A (es)
TW (1) TW200534844A (es)
WO (1) WO2005092294A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0221956D0 (en) * 2002-09-20 2002-10-30 Novartis Ag Organic compounds
AR048672A1 (es) * 2004-03-22 2006-05-17 Novartis Ag Tabletas de desintegracion que comprenden licarbazepina
US20060252745A1 (en) 2005-05-06 2006-11-09 Almeida Jose L D Methods of preparing pharmaceutical compositions comprising eslicarbazepine acetate and methods of use
WO2006121363A1 (en) * 2005-05-06 2006-11-16 Portela & C.A., S.A. Eslicarbazepine acetate and methods of use
GB0700773D0 (en) 2007-01-15 2007-02-21 Portela & Ca Sa Drug therapies
US8372431B2 (en) 2007-10-26 2013-02-12 Bial-Portela & C.A., S.A. Pharmaceutical composition comprising licarbazepine acetate
EP2683691B1 (en) 2011-03-08 2018-06-06 Jubilant Life Sciences Limited PROCESS FOR THE PREPARATION OF (S)-(+)-10,11-DIHYDRO-10-HYDROXY-5H-DIBENZ[b,f]AZEPINE-5-CARBOXAMIDE AND ESTERS THEREOF BY ENANTIOSELECTIVE REDUCTION OF 10,11-DIHYDRO-10-OXO-5H-DIBENZ[b,f]AZEPINE-5-CARBOXAMIDE
EP2498481A1 (en) 2011-03-09 2012-09-12 Sensirion AG Mobile phone with humidity sensor
JP2013237676A (ja) * 2013-06-26 2013-11-28 Bial-Portela & Ca Sa 酢酸エスリカルバゼピン及び使用方法
US10918604B2 (en) 2015-12-18 2021-02-16 Jubilant Generics Limited Solid oral dosage forms of eslicarbazepine

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5472714A (en) * 1993-09-08 1995-12-05 Ciba-Geigy Corporation Double-layered oxcarbazepine tablets
US6296873B1 (en) * 1997-01-23 2001-10-02 Yissum Research Development Company Of The Hebrew University Of Jerusalem Zero-order sustained release delivery system for carbamazephine derivatives
CO4920215A1 (es) * 1997-02-14 2000-05-29 Novartis Ag Tabletas de oxacarbazepina recubiertas de una pelicula y metodo para la produccion de estas formulaciones
IL125244A (en) * 1998-07-07 2002-12-01 Yissum Res Dev Co Pharmaceutical compositions containing low-melting waxes
MXPA04011801A (es) * 2002-05-31 2005-09-12 Desitin Arzneimittel Gmbh Composicion farmaceutica que contiene oxcarbazepina con liberacion controlada de la substancia activa.
WO2004014391A1 (en) * 2002-08-06 2004-02-19 Novartis Ag Use of carboxamides for the treatment of tinnitus
AR048672A1 (es) * 2004-03-22 2006-05-17 Novartis Ag Tabletas de desintegracion que comprenden licarbazepina

Also Published As

Publication number Publication date
IL177826A0 (en) 2006-12-31
BRPI0509067A (pt) 2007-08-21
US20070196488A1 (en) 2007-08-23
AU2005226910A1 (en) 2005-10-06
MA28527B1 (fr) 2007-04-03
ECSP066860A (es) 2006-11-24
EP1732519A1 (en) 2006-12-20
TW200534844A (en) 2005-11-01
NO20064808L (no) 2006-12-15
AR048318A1 (es) 2006-04-19
CA2558787A1 (en) 2005-10-06
JP2007529564A (ja) 2007-10-25
AU2005226910B2 (en) 2009-06-04
WO2005092294A1 (en) 2005-10-06
MXPA06010810A (es) 2006-12-15
RU2006137330A (ru) 2008-05-10

Similar Documents

Publication Publication Date Title
PE20051156A1 (es) Formulaciones de matriz orales que comprenden licarbazepina
ATE543491T1 (de) Kombinationspräparat enthaltend ibuprofen und paracetamol
AR026610A1 (es) Un derivado pirrolidinacetamida solo o en combinacion para tratamiento de desordenes del sistema nervioso central
CL2009000035A1 (es) Compuestos derivados 3-espiro-heterociclo-1il-5h-ciclopentan[d]pirimidin-indol, util para inhibir la actividad de akt quinasa; composicion farmaceutica que comprende dichos compuestos; y uso en el tratamiento de enfermedades tal como cancer, fibrosis quistica, diabetes, enfermedad de alzheimer, entre otras.
CY1118179T1 (el) Φαρμακευτικη συνθεση
GT199900203A (es) Composiciones de celecoxib.
AR054249A1 (es) Tratamiento de enfermedades del tejido conectivo de la piel
MA28921B1 (fr) Derive heterocyclique azote et medicament le contenant en tant que principe actif
AR045972A1 (es) Formulaciones de tramadol de liberacion sostenida con eficacia de 24 horas
MX2009002196A (es) Oblea de buprenorfina para terapia de sustitucion de farmacos.
AR058679A1 (es) Preparacion farmaceutica que contiene meloxicam
NO20065904L (no) Terapeutiske forbindelser
CL2008001820A1 (es) Compuestos derivados de aril-isoxasol-imidazol; procedimiento de preparacion; composicion farmaceutica que los contiene; y uso en la preparacion de medicamentos utiles en el tratamiento de trastornos cognitivos y enfermedades relacionadas con alzheimer.
PE20070333A1 (es) Composicion farmaceutica que comprende agomelatina para el tratamiento de transtornos del sueno en pacientes deprimidos
DE50005529D1 (de) Orale darreichungsformen zur verabreichung einer fixen kombination von tramadol und diclofenac
UY27759A1 (es) Combinaciones de medicamentos que contienen compuestos heterocíclicos y un nuevo agente anticolinérgico.
BR9916575A (pt) Composição farmacêutica de liberação controlada com mesilato de tilidina como substância-ativa
DE60102590T2 (de) Darreichungsformen zur behandlung von oralen mykosen
AR001765A1 (es) Una formulación de liberación prolongada un procedimiento para su preparación una forma cristalina de cisaprida-(l)-tartrato y un medicamento util para el tratamiento de trastornos gastrointestinales
CL2002001701A1 (es) Uso de al menos un compuesto seleccionado entre melatonina, agentes melatoninergicos, agonistas y antagonistas de melatonina, en una cantidad de 0,0025-50 mg, para preparar un medicamento util para el tratamiento y mejora de la calidad repadora del sueno.
SE0203817D0 (sv) New composition
UA87291C2 (ru) Пероральное пленкообразное лекарственное средство дезоксипеганина и способ его применения
AR048460A1 (es) Tratamiento de la funcion respiratoria alterada con gaboxadol
AR023763A1 (es) Agente que potencia la liberacion de acetilcolina en el cerebro
AU2002234644A1 (en) Use of 5-substituted nucleosides and/or prodrugs thereof in the resistance-free treatment of infectious diseases

Legal Events

Date Code Title Description
FD Application declared void or lapsed